HUP0300596A3 - Amorphous torasemide modification, process for its preparation its use and pharmaceutical compositions containing it - Google Patents
Amorphous torasemide modification, process for its preparation its use and pharmaceutical compositions containing itInfo
- Publication number
- HUP0300596A3 HUP0300596A3 HU0300596A HUP0300596A HUP0300596A3 HU P0300596 A3 HUP0300596 A3 HU P0300596A3 HU 0300596 A HU0300596 A HU 0300596A HU P0300596 A HUP0300596 A HU P0300596A HU P0300596 A3 HUP0300596 A3 HU P0300596A3
- Authority
- HU
- Hungary
- Prior art keywords
- preparation
- pharmaceutical compositions
- compositions containing
- torasemide modification
- amorphous torasemide
- Prior art date
Links
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 230000004048 modification Effects 0.000 title 1
- 238000012986 modification Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229960005461 torasemide Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HR20000162A HRP20000162B1 (en) | 2000-03-20 | 2000-03-20 | Amorphous torasemide modification |
PCT/HR2000/000011 WO2001070694A1 (en) | 2000-03-20 | 2000-05-02 | Amorphous torasemide modification |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0300596A2 HUP0300596A2 (hu) | 2003-07-28 |
HUP0300596A3 true HUP0300596A3 (en) | 2005-08-29 |
Family
ID=10947070
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0300596A HUP0300596A3 (en) | 2000-03-20 | 2000-05-02 | Amorphous torasemide modification, process for its preparation its use and pharmaceutical compositions containing it |
Country Status (29)
Country | Link |
---|---|
US (1) | US6767917B1 (hu) |
EP (1) | EP1272470B1 (hu) |
JP (1) | JP2003528083A (hu) |
KR (1) | KR20020093847A (hu) |
CN (1) | CN1211368C (hu) |
AR (1) | AR023788A1 (hu) |
AT (1) | ATE256662T1 (hu) |
AU (1) | AU2000241348A1 (hu) |
BG (1) | BG107208A (hu) |
BR (1) | BR0017175A (hu) |
CA (1) | CA2401908A1 (hu) |
CZ (1) | CZ20023436A3 (hu) |
DE (1) | DE60007360T2 (hu) |
EA (1) | EA004950B1 (hu) |
EE (1) | EE200200534A (hu) |
ES (1) | ES2213006T3 (hu) |
GE (1) | GEP20043300B (hu) |
HR (1) | HRP20000162B1 (hu) |
HU (1) | HUP0300596A3 (hu) |
IL (1) | IL151801A0 (hu) |
IS (1) | IS6551A (hu) |
MX (1) | MXPA02009210A (hu) |
NO (1) | NO20024464L (hu) |
PL (1) | PL357154A1 (hu) |
PT (1) | PT1272470E (hu) |
SK (1) | SK15092002A3 (hu) |
WO (1) | WO2001070694A1 (hu) |
YU (1) | YU70502A (hu) |
ZA (1) | ZA200208309B (hu) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6465496B1 (en) * | 1999-08-11 | 2002-10-15 | Teva Pharmaceutical Industries, Ltd. | Torsemide polymorphs |
IN192178B (hu) | 2001-08-03 | 2004-03-06 | Ranbaxy Lab | |
CA2536967A1 (en) | 2003-08-28 | 2005-03-17 | Nitromed, Inc. | Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use |
JP2008531579A (ja) | 2005-02-24 | 2008-08-14 | ニトロメッド インコーポレーティッド | 酸化窒素増強利尿化合物、組成物および使用方法 |
CN100421662C (zh) * | 2005-11-08 | 2008-10-01 | 周卓和 | 托拉塞米分散片及其制备方法和应用 |
CN104370805B (zh) * | 2013-08-13 | 2016-09-07 | 天津汉瑞药业有限公司 | 托拉塞米化合物 |
CN105949115A (zh) * | 2016-05-26 | 2016-09-21 | 南京正科医药股份有限公司 | 一种新晶型托拉塞米 |
CN115417810B (zh) * | 2022-09-22 | 2023-10-10 | 南京正科医药股份有限公司 | 一种托拉塞米晶型ⅰ的精制方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1477664A (en) * | 1974-04-17 | 1977-06-22 | Christiaens Sa A | Pyridine derivatives |
DE3529529A1 (de) * | 1985-08-17 | 1987-02-19 | Boehringer Mannheim Gmbh | Verfahren zur herstellung einer stabilen modifikation von torasemid |
GB8816620D0 (en) | 1988-07-13 | 1988-08-17 | Lepetit Spa | Rifapentine hydrohalides |
US6096779A (en) * | 1995-02-22 | 2000-08-01 | Hoechst Pharmaceuticals & Chemicals K.K. | Amorphous piretanide, piretanide polymorphs, process for their preparation and their use |
IN182496B (hu) | 1996-02-20 | 1999-04-17 | Reddy Research Foundation | |
HRP980532B1 (en) * | 1998-10-02 | 2005-06-30 | Pliva | Novel crystalline torasemide modification |
US5914336A (en) * | 1998-06-02 | 1999-06-22 | Boehringer Mannheim Gmbh | Method of controlling the serum solubility of orally administered torasemide and composition relating thereto |
US6465496B1 (en) | 1999-08-11 | 2002-10-15 | Teva Pharmaceutical Industries, Ltd. | Torsemide polymorphs |
-
2000
- 2000-03-20 HR HR20000162A patent/HRP20000162B1/xx not_active IP Right Cessation
- 2000-04-28 AR ARP000102019A patent/AR023788A1/es unknown
- 2000-05-02 MX MXPA02009210A patent/MXPA02009210A/es unknown
- 2000-05-02 JP JP2001568906A patent/JP2003528083A/ja active Pending
- 2000-05-02 GE GE4937A patent/GEP20043300B/en unknown
- 2000-05-02 AU AU2000241348A patent/AU2000241348A1/en not_active Abandoned
- 2000-05-02 EA EA200201003A patent/EA004950B1/ru not_active IP Right Cessation
- 2000-05-02 EE EEP200200534A patent/EE200200534A/xx unknown
- 2000-05-02 SK SK1509-2002A patent/SK15092002A3/sk unknown
- 2000-05-02 WO PCT/HR2000/000011 patent/WO2001070694A1/en not_active Application Discontinuation
- 2000-05-02 ES ES00920938T patent/ES2213006T3/es not_active Expired - Lifetime
- 2000-05-02 CZ CZ20023436A patent/CZ20023436A3/cs unknown
- 2000-05-02 BR BR0017175-1A patent/BR0017175A/pt not_active IP Right Cessation
- 2000-05-02 US US10/239,024 patent/US6767917B1/en not_active Expired - Fee Related
- 2000-05-02 CN CNB008194319A patent/CN1211368C/zh not_active Expired - Fee Related
- 2000-05-02 CA CA002401908A patent/CA2401908A1/en not_active Abandoned
- 2000-05-02 AT AT00920938T patent/ATE256662T1/de not_active IP Right Cessation
- 2000-05-02 YU YU70502A patent/YU70502A/sh unknown
- 2000-05-02 PT PT00920938T patent/PT1272470E/pt unknown
- 2000-05-02 DE DE60007360T patent/DE60007360T2/de not_active Expired - Fee Related
- 2000-05-02 EP EP00920938A patent/EP1272470B1/en not_active Expired - Lifetime
- 2000-05-02 HU HU0300596A patent/HUP0300596A3/hu unknown
- 2000-05-02 KR KR1020027012411A patent/KR20020093847A/ko not_active Application Discontinuation
- 2000-05-02 PL PL00357154A patent/PL357154A1/xx not_active Application Discontinuation
- 2000-05-02 IL IL15180100A patent/IL151801A0/xx unknown
-
2002
- 2002-09-17 IS IS6551A patent/IS6551A/is unknown
- 2002-09-18 NO NO20024464A patent/NO20024464L/no not_active Application Discontinuation
- 2002-10-15 ZA ZA200208309A patent/ZA200208309B/en unknown
- 2002-10-21 BG BG107208A patent/BG107208A/xx active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0301069A3 (en) | Novel biarylcarboxamides, process for their preparation, pharmaceutical compositions containing them and their use | |
HUP0301187A3 (en) | Novel benzyl-piperidine-derivatives, process for their preparation and pharmaceutical compositions containing them | |
HUP0300731A3 (en) | Valsartan salts, process for their preparation and pharmaceutical compositions thereof | |
HUP0300894A3 (en) | Substituted beta-carbolines, process for their preparation, pharmaceutical compositions containing them and their use | |
HUP0700086A2 (en) | 2-aminopyridine compounds, use thereof as drugs and pharmaceutical compositions containing them | |
HUP0204410A3 (en) | Pyrimidine-4-one derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
HUP0301315A3 (en) | Benzothiazole derivatives, process for their preparation, their use and pharmaceutical compositions containing them | |
HUP0402264A3 (en) | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines process for preparing them, pharmaceutical compositions containing them and use thereof | |
HUP0203902A3 (en) | Substituted oxazolidinones, process for their preparation and pharmaceutical compositions containing them and their use | |
HUP0303524A3 (en) | Novel quinuclidine derivatives, process for their preparation and medicinal compositions containing the same and their use | |
MXPA03004402A (es) | Composicion mejorada de sucralosa y procedimiento para su preparacion. | |
HUP0302480A3 (en) | Pyridinone derivatives for treatment of atherosclerosis, process for preparation thereof and pharmaceutical compositions containing the same | |
IL156662A0 (en) | Oxazolidinone derivatives, process for the preparation thereof and pharmaceutical compositions containing the same | |
HUP0301817A3 (en) | Kahalalide compounds, process for preparing thereof, pharmaceutical compositions comprising them and their use | |
HUP0302130A3 (en) | Combination pharmaceutical compositions and process for their preparation | |
IL154096A0 (en) | Aporphine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same | |
HUP0302295A3 (en) | Thienodibenzoazulene derivatives, process for their preparation and use thereof | |
HUP0204202A3 (en) | Ibuprofen containing active agent preparation, process for its preparation and pharmaceutical compositions containing it | |
HUP0100489A3 (en) | New piperidine-4-sulphonamide compounds, process for their preparation and pharmaceutical compositions containing them | |
HUP0302515A3 (en) | Sulfanidothienopyrimidines, process for their preparation and pharmaceutical compositions containing them | |
HUP0204394A3 (en) | Tetrahydropyridines, process for their preparation, pharmaceutical compositions containing them and use thereof | |
HUP0302429A3 (en) | 4-amino-quinazolines, process for producing them, pharmaceutical compositions containing them and their use | |
HUP0303105A3 (en) | Novel aminocyclohexane derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
HUP0204001A3 (en) | Substituted aminomethyl-phenyl-cyclohexane derivatives, process for their preparation and pharmaceutical compositions containing them | |
HUP0303361A3 (en) | Substituted 1-aminobutan-3-ol derivatives, process for their preparation and pharmaceutical compositions containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |